recent pharma news

Moderna announces dozing of first patient with its mRNA1273 vaccine The pharmaceutical company, Moderna, has been developing a vaccine for the treatment of COVID-19. The vaccine is an mRNA-1273 is developed by scientist at NAID, in collaboration with Moderna, and the manufacturing of the vaccine for Phase I clin...

The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC)  The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...

Killing brain tumors with the help of CAR-T CAR-T cell therapy is a technique which involves modifying patients' T cells to aim proteins associated with cancer that have revolutionized some of the blood cancers treatment. However, the technique has so far shown low potential in solid tumors like aggressive brain...

Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of USD 4.9 billion. By acquiring Forty Seven – named after its lead molecule - CD47 tumor cell protein - Gilead will acquire its lead candidate, Magrolimab, adding value to its ...

Formerly known as eptinezumab, Lundbeck’s Vyepti has received the recommendation from the US FDA for preventing migraine in adults. Estimated to affect women twice as compared to men, around 1.3billion people worldwide, and approximately 38 million people in the US are afflicted with Migraine.  With the gree...

Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has hit its primary endpoint. The back-to-back pivotal successes irked Incyte to talk to regulators regarding upcoming of the JAK inhibitor to market. Ruxoliti...

J&J collaborates with BARDA to accelerate coronavirus vaccine program Johnson & Johnson has collaborated with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to produce a vaccine against novel coronavirus. J&J is attempting to pool money and resources with BARDA in order to qu...

FDA has accepted Biological License Application submitted by Kite for its CAR-T cell therapy- KTE-X19, for relapsed or refractory mantle cell lymphoma (MCL) The drug- KTE-X19, which is an investigational chimeric antigen receptor (CAR) T cell therapy treatment method for curing relapsed or refractory mantle cell...

Activated immune cells responsible for improving age-related diseases  The main culprits of the inflammatory responses associated with asthma are Interleukins IL-33 and IL-5. There has been researching going on, and the researchers at Albany Medical College discovered that if these two signalling molecules ...

The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set to address the unmet needs in the Peanut market, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may ...